1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag

Invitation to SynAct's interim report Q4 2023 presentation

SynAct Pharma AB (publ) ("SynAct") will publish its Q4 report for 2023 on February 23 at 07.30 CET.

The company will host a conference call and online presentation on the same day at 15.00 CET. Torbjørn Bjerke, CEO, CFO Björn Westberg and Chief Business Officer Jim Knight will give an update on the development progress and financial results and will include a Q&A. The presentation will be made available on the website following the event.

The webcast will be live via the link: https://ir.financialhearings.com/synact-pharma-q4-2023/register

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference. 
https://conference.financialhearings.com/teleconference/?id=5003879


For further information, please contact:

Torbjørn Bjerke
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Email: TBJE@synactpharma.com
Email: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com. 

Attachments
Invitation to SynAct's interim report Q4 2023 presentation

Datum 2024-02-09, kl 14:27
Källa MFN
Bifogade filer
Invitation to SynAct's interim report Q4 2023 presentation
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!